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Clostridioides difficile (C. difficile), the microbe responsible for Clostridioides difficile 
infection (CDI), is a common nosocomial infection that exerts its pathogenicity primarily by two 
toxins, TcdA and TcdB. Designed ankyrin repeat proteins (DARPins) are an emerging approach 
of protein therapeutics to combat disease beyond the limitations of antibiotics and monoclonal 
antibodies. Disulfide bonds are commonly used in other facets of protein engineering to enhance 
stability, but their use has not been well documented with DARPins. Previously, the Chen lab 
engineered DARPins that have been demonstrated to be effective at neutralizing TcdB. However, 
these DARPins are not protease-stable, which is a barrier for effective delivery in downstream 
therapeutic contexts. To address this, disulfide bonds were introduced in order to increase the 
stability of the DARPins and thus increase resistance to protease digestion. The subsequent 
structure, stability, and neutralization activity are assessed to ascertain the effects of bolstering 
tertiary structure. The formation of disulfide bonds is confirmed by the comparison of mutants in 
oxidizing and reducing conditions. Elapsed trials with trypsin and chymotrypsin incubation 
demonstrate protease stability. Overall, the addition of disulfide bonds is demonstrated to 
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improve stability at minimal cost to neutralization activity. The successful characterization of 
these disulfide mutants may grant continuing insight into future protein engineering applications 
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BCA  Bicinchoninic acid 
BME  2-Mercaptoethanol 
BSA  Bovine serum albumin 
C. difficile Clostridioides difficile 
CDI  Clostridioides difficile infection 
DARPin Designed ankyrin repeat protein 
E. coli  Escherichia coli 
IPTG  Isopropyl β-D-1-thiogalactopyranoside 
LB  Luria-Bertani 
OD600 Optical density measured at 600 nm 
PAGE  Polyacrylamide gel electrophoresis 
PBS  Phosphate-buffered saline buffer 





 Designed ankyrin repeat proteins (DARPins) are an emerging approach of protein 
therapeutics to combat disease beyond the limitations of antibiotics and monoclonal antibodies 
(mAbs). The small molecular weight of this novel class of proteins gives it an advantageous 
pharmacokinetic profile, in addition to its high variability and high specificity-binding capacity, 
heat stability, and easy expression1. Furthermore, DARPins possess key qualities associated with 
low immunogenicity, having high stability, no aggregation tendency, and lacking an Fc domain2. 
Subsequently, the therapeutic potential of DARPins is great and is expanded by the multi-
specificity and functional modifications that can be engineered.   
Major potential for DARPins lies in the treatment of Clostridioides difficile (C. difficile), 
an obligate anaerobe, Gram-positive, spore-forming bacterium that is the leading cause of 
nosocomial infectious diarrhea worldwide3. Found in the gastrointestinal tract, C. difficile exerts 
its virulence by toxin A (TcdA) and toxin B (TcdB) and causes C. difficile infections (CDI)4. 
Standard treatment of CDI currently comprises the use of several antibiotics including 
vancomycin, metronidazole, and fidaxomicin3. The Centers for Disease Control and Prevention 
(CDC) have C. difficile marked as an urgent threat in regard to antibiotic resistance, underscoring 
the need for innovative therapeutics to lower the 12,800 deaths that occur from CDIs each year5.  
There are no DARPins currently in clinical use, although several candidates have 
progressed to clinical trials6,7. Previously, the Chen lab engineered DARPin constructs that were 
shown to be effective at neutralizing TcdB8. Additional DARPin constructs engineered were not 
protease-stable, which is a barrier for combating C. difficile activity in the small intestine4. Given 
the residence of C. difficile in the bowels, oral administration of therapeutics will allow for 
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increased bioavailability relative to systemic administration for this neutralizing mechanism of 
action. Orally administered DARPins must therefore be able to withstand the digestive processes 
all proteins are subjected to. To address this, disulfide bonds were introduced in order to increase 
the rigidity and stability of the DARPins and thus engineer them to be resistant to protease 
digestion. Three disulfide mutants were engineered – 1ss24, 41ss73, and 139ss148 – from parent 
DARPin T10-2 (Figure 1.1). Naming accordingly reflects the location of mutated cysteine 
residues, and thus putative disulfide formation, at the 1st and 24th residue, 41st and 73rd residue, 
and 139th and 148th residue accordingly.  
 
 
Figure 1.1: Locations of disulfide bonds are highlighted in red on a model of T10-2 from a Chimera visualization9 
Enhanced protein stability is a desirable goal for many biomedical applications, 
expanding the range over which a protein can retain its conformation and function. Disulfide 
bonds contribute to this stability by providing conformational constraints, thereby providing 
support to withstand a variety of environmental stressors10 and conferring protease resistance11. 
Although disulfides have been reported to add 2.5-5.1 kcal/mol to the thermodynamic stability of 
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a protein12, disulfides that destabilize structure have also been reported. The determinants for if 
inserted disulfide bonds will be stabilizing or destabilizing are under study13, and various 
bioinformatic models have been developed to better elucidate these elements and predict protein 
stability14.  
The formation of disulfide bonds is primarily influenced by the physical distance between 
cysteine residues, surrounding pH, and redox environment15. During protein synthesis, the 
cellular environment maintains reduced cysteine thiols; upon exiting the cell, where disulfide 
proteins most often enact their functions, exposure to oxygen provides an oxidizing environment 
in which these bridges can subsequently form13. Similarly, protein release upon cell lysis exposes 
DARPins to an oxidizing environment. DARPins are fast-folding proteins that assemble based 
on short-range interactions, favoring successful disulfide formation compared to slower folding 
proteins16,17. 
Disulfide bonds added in regions of flexibility that create large loops have been reported 
to increase stability, largely due to the ability of the backbone to adjust to optimal geometry for 
the disulfide bond18. In this study, residues linking ankyrin repeats within 2.3 Å were identified 
and mutated into cysteine residues. While the peptide backbone is planar and limited in rotation, 
the Cα–C and N–Cα bonds are able to rotate19, meaning the primary consideration for disulfides 
bridges here was ensuring the physical proximity of cysteine β-carbons and avoiding introducing 
steric strain in the native conformation.  
Despite its growing utility in other facets of protein engineering13, the use of disulfide 
bonds has not been well documented with DARPins. The enhancement in stability that disulfide 
bridges can provide offers a promising avenue to improve the activity of neutralizing DARPins. 
The characterization of these DARPin mutants is subsequently necessary to determine structure, 
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stability, binding affinity, and neutralization activity. An increase in protease-stability at 
marginal cost to neutralization activity will be informative to future studies on protein 





2.1 Disulfide Mutant Expression and Purification 
Shuffle E. coli containing plasmid DNA encoding the disulfide mutants were inoculated 
in 5 mL of LB broth with 50 µg/mL Kanamycin and cultured at 37ºC. After 16 hours, each 
culture was transferred into 100 mL of LB broth with 50 µg/mL Kanamycin and cultured until 
OD600 values between 0.4 and 0.8 were measured with a spectrophotometer. Protein expression 
was induced with 0.4 mM IPTG and kept at 18ºC for 18 hours. Cells were collected by 
centrifugation and lysed via sonification. Samples were centrifuged and the supernatant collected 
for purification of soluble proteins. Purification was performed by Ni-NTA affinity column 
chromatography. Two rounds of washes were performed twice: one set with PBS and the other 
with PBS containing 30 mM imidazole. Purified protein was eluted with PBS containing 150 
mM imidazole. The DARPins were buffer exchanged into PBS and concentrated by 10k Amicon 
ultra centrifugal filters. SDS-PAGE was performed to confirm expression and purification. 
Samples were flash-frozen with liquid nitrogen and kept at -80 ºC. 
 
2.2 Disulfide Mutant Concentration Determination 
 To ascertain protein concentrations from measured nanodrop concentrations, a BCA 
protein assay was used to quantify total protein and determine a corresponding extinction 




2.3 Disulfide Bond Formation Confirmation 
Disulfide bond confirmation was performed by analysis of varied SDS-PAGE run 
conditions. Two samples of each DARPin were electrophoresed: one sample with loading buffer 
containing BME, and one without. Samples were heated at 95ºC for five minutes, then loaded 
onto a 12% acrylamide SDS-PAGE at 200V for 45 minutes. Staining was performed with 
Coomassie blue. 
 
2.4 Protease Digestion Trials 
Disulfide DARPin stability was assessed in the presence of trypsin and chymotrypsin. 
DARPins were diluted to 0.5 mg/mL in PBS. 100 µL of trypsin slurry was combined with each 
DARPin and incubated for 3 hours. Similarly, 25 µL of chymotrypsin slurry was combined with 
each DARPin and incubated for 3 hours. At each hour (0, 1, 2, 3), samples were collected and 
kept at -20ºC. A native PAGE was run to assess protein conformation and stability. The parent 
DARPin T10-2 was used as a control. 
 
2.5 Cell Viability Assay 
The ability of DARPins to maintain cell viability in the presence of TcdB was measured 
with Vero E6 cells. Cells were seeded at a density of 1.5 × 103 cells/well overnight. DARPins 
were incubated with either PBS, 1 mg/mL trypsin, or 0.5 mg/mL chymotrypsin for 1 hour at 
37ºC. For each DARPin, a five-fold serial dilution series was constructed from 0.0016 nM to 125 
nM. These protein dilutions were added to the cells following incubation, as was 1.1 pg/mL 
TcdB. Cells were thereafter incubated at 37ºC for 72 hours. Cell viability was determined from 
ATP levels by measuring luminescence with CellTiter-Glo. All aforementioned procedures were 
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repeated with T10-2 and 139ss148 altering the initial incubation to be with PBS, 0.5 mg/mL 




3.1 Disulfide Bond Confirmation 
As the proteins were denatured by the presence of SDS and application of heat, 
differences in band migration can be attributed to the presence of disulfide bonds. The presence 
of a disulfide bond alters the migration of the protein such that DARPins that exhibit the same 
run pattern in reducing conditions (with BME) and oxidizing conditions (without BME) lack a 
disulfide bond; conversely, DARPins with dissimilar run patterns in these conditions contain a 
disulfide bond. As expected, T10-2, which lacks cysteines, displayed the same migration pattern 
in reducing and oxidizing conditions (Figure 3.1). Similarly, 41ss73 displayed the same run 
pattern in both conditions and was determined to not have formed a disulfide bond. The 1ss24 
and 139ss148 mutants displayed a difference in band migration between redox conditions and 
were confirmed as having successfully formed disulfide bonds. Given the naturally oxidizing 
conditions of the exposed in vitro setting and close proximity, the absence of a disulfide bridge 
in 41ss73 may be the result of conformational strain imposed on the backbone to accommodate 






Figure 3.1: SDS-PAGE of T10-2 and disulfide mutants in reducing and oxidizing conditions. + indicates the 
addition of BME, - indicates the absence of BME. 
 
3.2 Disulfide Mutants are Stable in the Presence of Trypsin  
Disulfide DARPin mutants were incubated with trypsin for three hours to assess if 
original conformation was retained in the presence of proteases found in the intestinal tract. 
When electrophoresed on a native PAGE, all DARPins exhibited a consistent appearance over 
three hours (Figure 3.2, 3.3). This confirms the trypsin stable nature of the disulfide mutants. The 
introduction of the disulfide bonds did not interfere with the trypsin resistant nature of T10-2 




Figure 3.2: Native PAGE of T10-2 and 1ss24 after incubation with trypsin over 3 hours. 
 
 




3.3 Disulfide Mutants are Stable in the Presence of Chymotrypsin 
With trypsin stability established, disulfide DARPin mutants were then incubated with 
chymotrypsin for three hours to assess if they likewise retained their original conformation 
despite protease activity. From native PAGE analysis, the initial DARPin conformation is 
revealed to be best maintained over the course of 3 hours in 1ss24 and 139ss148 (Figure 3.4, 
3.5). In contrast, parent T10-2 is digested by chymotrypsin; the progressively dimmed protein 
band intensity over time in comparison and smear seen in hours 1-3 indicates the loss of 
conformation. Sustained band intensity by disulfide mutants in the presence of trypsin and 










Figure 3.5: Native PAGE of 41ss73 and 139ss138 after incubation with chymotrypsin over 3 hours. 
 
3.4 DARPin Disulfide Mutant 139ss148 and T10-2 Display Comparable Neutralization 
Activity 
The effect of DARPin concentration when comparing cell viability in the presence and 
absence of proteases models physiological conditions that DARPins would be administered in 
for downstream therapeutic applications. Consistent with lack of disulfide bond formation and 
poorer performance in the digestion trials, 41ss73 demonstrated little neutralization activity in 





Figure 3.6: Cell rescuing activity of 41ss73 against TcdB in the presence of trypsin and chymotrypsin 
 
1ss24 displayed robust neutralization activity (Figure 3.7), and 139ss148 had the best 
activity of the disulfide mutants in the presence of chymotrypsin (Figure 3.8). The enhanced 
performance seen in these two mutants relative to 41ss73 reflects the protease resistance 
observed in the protease digestion trials.  
 





Figure 3.8: Cell rescuing activity of 139ss148 against TcdB in the presence of trypsin and chymotrypsin 
 
Given the robust performance of 139ss148, its activity was assessed in varied 
chymotrypsin concentrations against T10-2 from which it was derived. Between 0.5 mg/mL and 
1.0 mg/mL of chymotrypsin, 139ss148 was similarly effective in rescuing cells from the 
cytotoxic effects of TcdB (Figure 3.9). T10-2 also exhibited consistent rescuing activity (Figure 
3.10). Overall, the performance of the two DARPins was comparable, with both 139ss148 and 





Figure 3.9: Cell rescuing activity of 139ss148 against TcdB in the presence of varied chymotrypsin concentrations 
 
 






4.1 Disulfide Bond Effects 
Select disulfide mutant DARPins did appear to have enhanced stability, although not 
subsequently demonstrating improved neutralization activity. The introduction of disulfide bonds 
had varied augments on protease stability. 1ss24 and 139ss148 chymotrypsin resistance was 
superior to that of 41ss73, suggesting that the presence of a disulfide bond at the N or C terminus 
is more critical to maintaining protein conformation than a bond in the central ankyrin domains. 
As protein unfolding is required before cleavage can occur, the maintenance of secondary and 
tertiary structures subverts this process. By introducing these disulfide bridges at the terminals of 
the DARPin, access to cleavage sites is limited and allows for conformational stability despite 
protease activity.  
 
4.2 Future Directions 
DARPins are generally resistant to mutation and stable in the established repeated 
ankyrin structures. Here, the introduction of disulfides and stability was experimentally verified. 
139ss148 was demonstrated to have similar performance to T10-2 from which it was created. 
Ultimately, a DARPin with improved performance to that of T10-2 is desirable, and various 
avenues exist to engineer such a protein. Among these, the combination of the disulfide bond at 
the 1st and 24th residues with the bond at 139th and 148th residues may exhibit further improved 
stability and neutralization activity. This introduces the challenge of ensuring optimal disulfide 
bond formation, as the presence of more than two cysteine residues expands the possible 
combinations of disulfide bond formation20–22. However, proper formation is still enhanced in 
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small, fast-folding proteins, and promoted through the use of proteins such as protein disulfide 
isomerase23. As demonstrated here, singular disulfide bonds were limited in their capacity to 
enhance TcdB neutralization. Although these alone were insufficient for improved activity, 
additional studies in tandem with other stabilizing modifications may prove useful to develop a 
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